Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

BridgeBio Pharma Earnings Call: Key Takeaways

BridgeBio is transitioning to a multi-product commercial stage company with $253.2M in Acaramidus revenue and three major FDA PDUFA dates scheduled within the next seven months.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthUS Acaramidus $253.2M, up 134% YoY; Royalties $20.5M, up from $4.3M.
Mgmt ConfidenceHigh confidence in meeting or beating $4B peak-year sales for Acaramidus.
Demand VisibilityIdentified 500 LGMD2I patients and 600 ADH1 patients ahead of launch.
Margin TrendsOperating loss improved to $11.6M from $145.2M loss year-over-year.
Op. LeverageAnticipate margin expansion as Acaramidus scales and three new products launch.
Pricing PowerGross-to-net remains stable; 90% approval rates through payer appeals.
Vol vs PriceGrowth predominantly driven by first-line new patient starts.
Segment GrowthAcaramidus leading brand in Europe; $75M milestone from Bayer partnership.
New ClientsReached 70% of MDA Care Centers; 2,900 physicians have prescribed Acaramidus.
Capex & Debt$1.5B cash on hand; executed share buybacks in September.
RegulatoryThree priority reviews: BBP-418 (Nov 27), Infigratinib (Feb 4), Incalorant (May 8).
CommentaryEmphasized reducing information asymmetry and using AI for modern commercial execution.
New LaunchesBBP-418 for LGMD2I, Infigratinib for Achondroplasia, and Incalorant for ADH1.

Growth

Total revenue $353.2M; US Acaramidus revenue $253.2M, up 134% year-over-year and 14% quarter-over-quarter.

Outlook

Targeting $4B peak sales for Acaramidus and $4B combined for three upcoming launches.

Risks

Management used vague language regarding the specific impact of potential 340B and ASP legislative changes.

Source

The company's earnings call, NASDAQ: BBIO, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

BridgeBio Pharma, Inc.: key numbers

Share price
$77.36Close, Nov 16
Market cap
$15.1B
Shares outstanding
194.8MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from BridgeBio Pharma, Inc.

All →
4:15 PM ET Form 4
Insider Selling

BridgeBio Pharma CAO Maricel Apuli Sells $146K of Stock

Maricel Apuli, CAO, sold 2,000 shares of BridgeBio Pharma, Inc. at $72.85 a share, worth $146K in total on Oct 30, 2026. Shares held after the trade: 120,687 (-1.6%).

Value
$146K
Shares
2,000
Price
$72.85
Role
CAO
Holding change
-1.6%
Trade date
Oct 30, 2026
4:52 PM ET 10-Q
Financial Results ▶ Call

BridgeBio Pharma Q3 2026 Results: Net Loss of $56.7M, Loss Narrows

BridgeBio Pharma reported a significant increase in total revenues to $791.4 million for the first nine months of 2026, driven primarily by net product revenue from Attruby and Beyonttra. Despite the revenue growth, the company maintained a net loss of $382.9 million due to high research and development and selling expenses, though this was an improvement from the $538.3 million loss in the prior year period.

Key figure
Net loss $56.7M
4:03 PM ET 8-K
Financial Results

BridgeBio Pharma Financial Results

BridgeBio Pharma reported Q3 2026 financial results, highlighted by $353.2 million in total revenue, including $253.2 million from U.S. Attruby net product sales. The company is preparing for three potential product launches in 2026 and 2027 for BBP-418, oral infigratinib, and encaleret, all of which have been granted Priority Review by the FDA.

Term
Q3 2026
6:03 AM ET 8-K
Business Update

BridgeBio Pharma Business Update

BridgeBio Pharma announced that the FDA has accepted its New Drug Application (NDA) for oral infigratinib for the treatment of children with achondroplasia and granted it Priority Review. The FDA has assigned a PDUFA target action date of February 4, 2027, for the potential approval of what would be the first oral therapy for this condition. The filing is supported by Phase 3 PROPEL 3 data showing significant improvements in annualized height velocity and body proportionality.

Counterparty
FDA
6:21 PM ET Form 4
Insider Selling

BridgeBio Pharma CEO Neil Kumar Sells $691K of Stock

Neil Kumar, CEO, sold 10,000 shares of BridgeBio Pharma, Inc. at $69.01 to $69.57 a share (average $69.08) in 2 transactions, worth $691K in total on Sep 17, 2026. Shares held after the trade: 495,686 (-0.3%).

Value
$691K
Shares
10,000
Average price
$69.08
Role
CEO
Holding change
-0.3%
Trade date
Sep 17, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.